AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
| Revenue (TTM) | $66.17M |
| Gross Profit (TTM) | $-131.60M |
| EBITDA | $-199.96M |
| Operating Margin | -1550.00% |
| Return on Equity | -17.30% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $2.92 |
| Price-to-Book | 4.18 |
| Price-to-Sales (TTM) | 55.97 |
| EV/Revenue | 50.55 |
| EV/EBITDA | 5.30 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | -76.30% |
| Shares Outstanding | $324.05M |
| Float | $209.04M |
| % Insiders | 21.74% |
| % Institutions | 36.68% |
Volatility is currently contracting
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026.
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABCL and any ticker you trade — then tracks every position and per-strategy win rate.
